Philippe JEAN-PIERRE

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/10/2021
• Auteurs : Vincent MalletLucia ParlatiAlessandro MartininoJuan Pablo Scarano PereiraCarmen Navas JimenezMehdi SakkaSamir BouamAurelia RetbiDonika KrastevaJean Francois MeritetMichael SchwarzingerDominique ThabutPierre RufatDominique Bonnefont-RousselotPhilippe SogniStanislas PolEmmanuel TsochatzisGroup Demosthenes Research
• Organismes : Bordeaux population health Unité de Technologies Chimiques et Biologiques pour la Santé
• Publié dans Journal of Hepatology le 23/10/2020

---

Résumé : BACKGROUND AND AIMS: There are uncertainties on the burden of liver disease in patients with type-2 diabetes (T2D). METHODS: We measured adjusted hazard ratios of liver disease progression to hepatocellular cancer and/or decompensated cirrhosis in a 2010-2020 retrospective, bicentric, longitudinal, cohort of 52,066 hospitalized patients with T2D. RESULTS: Mean age was 64±14 years and 58% were men. Alcohol use disorders accounted for 57% of liver-related complications and were associated with all liver-related risk factors. Non-metabolic liver-related risk factors accounted for 37% of the liver burden. T2D control was not associated with liver disease progression. The incidence (95% confidence interval) of liver-related complications and of competing mortality were 3.9 (3.5-4.3) and 27.8 (26.7-28.9) per 1000 person-years at risk, respectively. The cumulative incidence of liver disease progression exceeded the cumulative incidence of competing mortality only in the presence of a well-identified risk factors of liver disease progression, including alcohol use. The incidence of hepatocellular cancer was 0.3 (95% CI, 0.1-0.5) per 1000 person-year in patients with obesity and it increased with age. The adjusted hazard ratios of liver disease progression were 55.7 (40.5-76.6), 3.5 (2.3-5.2), 8.9 (6.9-11.5), and 1.5 (1.1-2.1), for alcoholic liver disease, alcohol use disorders without alcoholic liver disease, non-metabolic liver-related risk factors, and obesity, respectively. The attributable fractions of alcohol use disorders, non-metabolic liver risk-related risk factors, and obesity to the liver burden were 55%, 14%, and 7%, respectively. CONCLUSIONS: In this analysis of data from two hospital-based cohorts of patients with T2D, alcohol use disorders, rather than obesity, contributed to most of the liver burden. These results suggest that patients with T2D should be advised to drink minimal amounts of alcohol. LAY SUMMARY: • There is uncertainty on the burden of liver-related complications in patients with type-2 diabetes • We studied the risks of liver cancer and complications of liver disease in over 50,000 patients with type-2 diabetes • We found that alcohol was the main factor associated with complications of liver disease • This finding has major implications on the alcohol advice given to patients with type-2 diabetes.

---

Fichiers liés : S0168827821020924.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/10/2021
• Auteurs : Djillali AnnaneMartin RottmanNicholas HemingVéronique GodotJérôme FleurietJean Sébastien BlanchetPierre MoineLamiae GrimaldiSylvie ChevretAnnane DjillaliMoine PierreHeming NicholasMaxime VirginieClair BernardOrlikowski DavidBouneb RaniaMurg EleonoraAbdeladim LiliaFayssoil AbdallahBlanchet Jean-SébastienChevret SylvieDaniel ChristelDevillier PhilippeFleuriet JéromeFrançois BrunoGarchon Henri-JeanGodot VéroniqueGrassin-Delyle StanislasGrimaldi LamiaeKedad ZoubidaLassalle PhilippeU. Richly MaximilianRottman MartinRoux Anne-LaureTalini LucZeitouni KarineDjillali AnnaneValérie BardetXavier MonnetLamiae GrimaldiSylvie ChevretAnne-Laure RouxMartin RottmanStanislas Grassin DelyleHenri-Jean GarchonXavier MonnetAntoine Vieillard-BaronGuillaume GériZiad MassyJean-Claude AlvarezMarie EssigAmine LarabiValérie BardetBruno MégarbaneNicholas HemingPierre TissièresFrançois FayMarie-Anne Rameix-WeltiBruno MégarbanePierre MoineKarine ZeitouniLaurent DumasZaineb ChellyMartin RottmanAnne-Laure RouxLoïc JosseranMahmoud Zureik
• Organismes : Optimisation thérapeutique en Neuropsychopharmacologie
• Publié dans Intensive Care Medicine le 27/10/2020

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/10/2021
• Auteurs : Claire BouletiMorgane MichelAntoine Jobbe DuvalThibaut HemeryPierre-Philippe NicolRomain DidierFloriane ZeyonsOualid ZouaghiDidier TchetcheClemence DelonMaxence DelomezAlain DibieDavid AttiasHerve Le BretonBertrand CormierJean-Francois ObadiaChristophe TribouilloyEmmanuel LansacKarine ChevreulNicole NaccacheHelene EltchaninoffMartine GilardBernard Iung
• Organismes : Centre hospitalier universitaire de Poitiers = Poitiers University Hospital Université de Poitiers – UFR Santé [Faculté de Médecine et de Pharmacie] CIC de Poitiers – Centre d'investigation clinique de Poitiers (CIC 1402) Epidémiologie Clinique et Evaluation Economique Appliquées aux Populations Vulnérables Endothélium, valvulopathies et insuffisance cardiaque CHU Rouen Hôpital de la Cavale Blanche Service de cardiologie [Brest] Hôpitaux Universitaires de Strasbourg Clinique Pasteur [Toulouse] Institut Mutualiste de Montsouris Clinique Pasteur [Toulouse] Laboratoire Traitement du Signal et de l'Image Hôpital Privé Jacques Cartier [Massy] Hospices Civils de Lyon Université de Picardie Jules Verne Mécanismes physiopathologiques et conséquences des calcifications cardiovasculaires - UR UPJV 7517 Institut Mutualiste de Montsouris Epidémiologie Clinique et Evaluation Economique Appliquées aux Populations Vulnérables Département de la Recherche Clinique et du Développement [AP-HP Hôtel Dieu] Endothélium, valvulopathies et insuffisance cardiaque CHU Rouen Optimisation des régulations physiologiques Laboratoire de Recherche Vasculaire Translationnelle
• Publié dans Archives of cardiovascular diseases le 30/10/2020

---

Résumé : Background. - According to the guidelines, surgical aortic valve replacement (SAVR) is recommended in patients at low surgical risk (EuroSCORE II < 4%), whereas for other patients, the decision between transcatheter aortic valve implantation (TAVI) and surgery should be made by the Heart Team, with TAVI being favoured in elderly patients. Aim. - The RAC prospective multicentre survey assessed the respective contributions of age and surgical risk scores in therapeutic decision making in elderly patients with severe symptomatic aortic stenosis. Methods. - In September and October 2016, 1049 consecutive patients aged >= 75 years were included in 32 centres with on-site TAVI and surgical facilities. The primary endpoint was the decision between medical management, TAVI or SAVR. Results. - Mean age was 84 +/- 5 years and 53% of patients were female. The surgical risk was classified as high (EuroSCORE II > 8%) in 18% of patients, intermediate (EuroSCORE II 4-8%) in 34% and low (EuroSCORE II <= 4%) in 48%. TAVI was preferred in 71% of patients, SAVR in 19% and medical treatment in 10%. The choice of TAVI over SAVR was associated with older age (P < 0.0001) and a higher EuroSCORE II (P = 0.008). However, the weight of EuroSCORE II in therapeutic decision making markedly decreased after the age of 80 years. Indeed, 77% of patients aged >= 80 years were referred for TAVI, despite a low estimated surgical risk. Conclusions. - The impact of risk scores depends strongly on age, and decreases considerably after 80 years, most patients being referred for TAVI, independent of their estimated surgical risk. Despite medical advancements, 10% of patients were still denied any intervention. (C) 2021 Elsevier Masson SAS. All rights reserved.

---

Fichiers liés : S1875213621001352.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/10/2021
• Auteurs : Francis BessièreKévin GardeyAbdeslam BouzemanGuillaume DuthoitLinda KoutbiFabien LabombardaChristelle MarquiéJean-Baptiste GourraudPierre MondolyJean Marc SellalPierre BordacharAlexis HermidaFrédéric AnselmeAnouk AsselinCaroline AudinetYvette BernardSerge BovedaPhilippe ChevalierGael ClericiAntoine da CostaMaxime de GuillebonPascal DefayeRomain EschalierRodrigue GarciaCharles GuenanciaBenoit Guy-MoyatRoland HenaineDidier IrlesLaurence IserinFrançois JourdaMagalie LadouceurPhilippe LagrangeMikael LaredoJacques MansouratiGrégoire MassouliéAmel MathironPhilippe MauryCédric NguyenSandro NinniMarie-Cécile PerierBertrand PierreFrédéric SacherCamille WaltonPierre WinumRaphaël P MartinsJean-Luc PasquiéJean Benoit ThamboXavier JouvenNicolas CombesSylvie Di FilippoEloi MarijonVictor Waldmann
• Organismes : Hôpital Louis Pradel [CHU - HCL] Hôpital Louis Pradel [CHU - HCL] CHU Pitié-Salpêtrière [AP-HP] Hôpital de la Timone [CHU - APHM] CHU Caen Normandie – Centre Hospitalier Universitaire de Caen Normandie Centre Hospitalier Régional Universitaire [CHU Lille] Centre Hospitalier Universitaire de Nantes = Nantes University Hospital Centre Hospitalier Universitaire de Toulouse Imagerie Adaptative Diagnostique et Interventionnelle Centre Hospitalier Régional Universitaire de Nancy Centre Hospitalier Universitaire de Bordeaux CHU Amiens-Picardie CHU Rouen Paris-Centre de Recherche Cardiovasculaire Groupe Hospitalier Bretagne Sud Centre Hospitalier Régional Universitaire de Besançon Clinique Pasteur [Toulouse] Hôpital Louis Pradel [CHU - HCL] CHU Sud Saint Pierre [Ile de la Réunion] Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] Centre hospitalier de Pau Centre Hospitalier Universitaire [CHU Grenoble] CHU Clermont-Ferrand Centre hospitalier universitaire de Poitiers = Poitiers University Hospital CHU Dijon CHU Limoges Hôpital Louis Pradel [CHU - HCL] Hôpital Européen Georges Pompidou [APHP] Paris-Centre de Recherche Cardiovasculaire CHU Pitié-Salpêtrière [AP-HP] Centre Hospitalier Régional Universitaire de Brest Optimisation des régulations physiologiques CHU Clermont-Ferrand CHU Amiens-Picardie Centre Hospitalier Régional Universitaire de Nancy Centre Hospitalier Chalon-sur-Saône William Morey Centre Hospitalier Régional Universitaire [CHU Lille] Paris-Centre de Recherche Cardiovasculaire Centre Hospitalier Régional Universitaire de Tours Centre Hospitalier Universitaire de Bordeaux Hôpital Louis Pradel [CHU - HCL] Centre Hospitalier Universitaire de Nîmes Physiologie & médecine expérimentale du Cœur et des Muscles [U 1046] Centre Hospitalier Régional Universitaire [Montpellier] Centre Hospitalier Universitaire de Bordeaux Paris-Centre de Recherche Cardiovasculaire Paris-Centre de Recherche Cardiovasculaire Hôpital Louis Pradel [CHU - HCL] Paris-Centre de Recherche Cardiovasculaire Paris-Centre de Recherche Cardiovasculaire
• Publié dans JACC: Clinical Electrophysiology le 31/10/2020

---

Résumé : Objectives: This study aimed to assess the impact of pulmonary valve replacement (PVR) on ventricular arrhythmias burden in a population of tetralogy of Fallot (TOF) patients with continuous cardiac monitoring by implantable cardioverter-defibrillators (ICDs). Background: Sudden cardiac death is a major cause of death in TOF, and right ventricular overload is commonly considered to be a potential trigger for ventricular arrhythmias. Methods: Data were analyzed from a nationwide French ongoing study (DAI-T4F) including all TOF patients with an ICD since 2000. Survival data with recurrent events were used to compare the burden of appropriate ICD therapies before and after PVR in patients who underwent PVR over the study period. Results: A total of 165 patients (mean age 42.2 ± 13.3 years, 70.1% male) were included from 40 centers. Over a median follow-up period of 6.8 (interquartile range: 2.5 to 11.4) years, 26 patients (15.8%) underwent PVR. Among those patients, 18 (69.2%) experienced at least 1 appropriate ICD therapy. When considering all ICD therapies delivered before (n = 62) and after (n = 16) PVR, the burden of appropriate ICD therapies was significantly lower after PVR (HR: 0.21; 95% confidence interval [CI]: 0.08 to 0.56; p = 0.002). Respective appropriate ICD therapies rates per 100 person-years were 44.0 (95% CI: 35.7 to 52.5) before and 13.2 (95% CI: 7.7 to 20.5) after PVR (p < 0.001). In the overall cohort, PVR before ICD implantation was also independently associated with a lower risk of appropriate ICD therapy in primary prevention patients (HR: 0.29 [95% CI: 0.10 to 0.89]; p = 0.031). Conclusions: In this cohort of high-risk TOF patients implanted with an ICD, the burden of appropriate ICD therapies was significantly reduced after PVR. While optimal indications and timing for PVR are debated, these findings suggest the importance of considering ventricular arrhythmias in the overall decision-making process. (French National Registry of Patients With Tetralogy of Fallot and Implantable Cardioverter Defibrillator [DAI-T4F]; NCT03837574).

---

Fichiers liés : 2021 Bessiere et al., Impact.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/10/2021
• Auteurs : Tanguy VendeuvrePaul BrossardJean-Baptiste PicMaxime BillotLouis-Etienne GayetPierre PriesSimon TeyssédouArnaud GermaneauPhilippe Rigoard
• Organismes : Photomécanique et analyse expérimentale en mécanique des solides [Institut Pprime] Photomécanique et analyse expérimentale en mécanique des solides [Institut Pprime] Institut Pprime [UPR 3346] Photomécanique et analyse expérimentale en mécanique des solides [Institut Pprime]
• Publié dans European Spine Journal le 23/10/2020

---

Résumé : Objective To compare radiologically balloon kyphoplasty (BKP) and vertebral compression fracture (VCF) expansion and corroborate with a finite element (FE) analysis. The principle of BKP is to stabilize VCF by restoring vertebral body anatomy using bone expansion and cement filling. More recently, vertebral body stenting (VBS) has been developed to reduce the loss of vertebral height observed after balloon deflation. Methods A retrospective, monocentric and continuous study of 60 non-osteoporotic fractures of the thoracolumbar junc- tion treated by vertebral bone expansion was carried out over three years. The main endpoint was radiological correction of vertebral kyphosis (VK) at 3 months. The other studied parameters were vertebral height, index of Farcy, index of Beck, cement leakages and their location. A FE model was developed to analyze effects linked to the stent during cement injection, specifically throughout the risk of cement leakage evaluation. Results After three months, average reduction of VK was 4.73° ± 4.8° after BKP, and 4.63° ± 2.7° after VBS. There was no difference between the two techniques, but cement leakage was significantly greater with BKP (41.7%) than with VBS (4.2%). FE analysis showed substantial changes of the cement flow orientation in the presence of a stent. Conclusion BKP and VBS offer comparable expansion with no added value of VBS in non-osteoporotic VCF reduction. VBS technique appears to prevent cement leakage due to its mesh architecture hindering the leaking process. In counterpart, such balloon expansion is likely to require higher pressure to deploy the stent. This could be an important parameter to take into account in young patients with high bone density.

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/10/2021
• Auteurs : Ian-Christopher TanohElisabeth MaillartPierre M LabaugeMikael CohenAdil MaaroufSandra VukusicCécile DonzéPhilippe GallienJérôme de SèzeBertrand BourreThibault MoreauCéline LouapreMorgane ValléeSéverine BieuveletLissandra KlaeyléAnne-Laure ArgoudSaad ZinaïAyman Tourbah
• Organismes : Laboratoire d'informatique de l'École polytechnique [Palaiseau] CHU Pitié-Salpêtrière [AP-HP] Centre Hospitalier Régional Universitaire [Montpellier] Université de Montpellier Hôpital Pasteur [Nice] Centre de résonance magnétique biologique et médicale Assistance Publique - Hôpitaux de Marseille Service de Neurologie [Lyon] Centre de recherche en neurosciences de Lyon - Lyon Neuroscience Research Center Unité de traitement des signaux Biomédicaux Centre Hospitalier Régional Universitaire [CHU Lille] Médecine Physique et de Réadaptation [Rennes] Biopathologie de la Myéline, Neuroprotection et Stratégies Thérapeutiques Service de neurologie [Rouen] Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand CHU Pitié-Salpêtrière [AP-HP] Institut du Cerveau = Paris Brain Institute Institut du Cerveau = Paris Brain Institute CHU Pitié-Salpêtrière [AP-HP] CHU Pitié-Salpêtrière [AP-HP] Institut du Cerveau = Paris Brain Institute CHU Pitié-Salpêtrière [AP-HP] Institut du Cerveau = Paris Brain Institute CHU Pitié-Salpêtrière [AP-HP] Institut du Cerveau = Paris Brain Institute CHU Pitié-Salpêtrière [AP-HP] Institut du Cerveau = Paris Brain Institute Laboratoire de Psychopathologie et Neuropsychologie Hôpital Raymond Poincaré [AP-HP] UFR Sciences de la santé Simone Veil
• Publié dans Multiple Sclerosis and Related Disorders le 24/10/2020

---

Résumé : Background: A previous clinical study showed the high specificity, sensitivity and reliability of MSCopilot, a software medical device designed by Ad Scientiam for the self-assessment of people with Multiple Sclerosis (PwMS), compared to the traditional Multiple Sclerosis Functional Composite (MSFC). We conducted further analyses to assess MSCopilot's performance with respect to the Expanded Disability Status Scale (EDSS).Methods: The data of 116 PwMS were analysed. We studied the correlations between MSCopilot scores and the EDSS, and their ability to distinguish PwMS with high and low EDSS through a study of the distribution of the digital test scores as well as logistic regression models. The same analyses were performed using the MSFC tests.Results: MSCopilot composite scores were as highly correlated to the EDSS (|r| = 0.65, p < 0.01) as their MSFC counterparts, confirming the known correlation of the MSFC with the EDSS. In a linear regression framework, the Walking digital tests have good explanatory power, especially for PwMS with EDSS > 3.5 (R²adj=0.47). The mean values of each MSCopilot subscore were significantly different between patients with an EDSS > 3.5 and others (p < 0.05), which could not be proved for the MSFC Cognition tests. MSCopilot4 was the best model to predict an EDSS score > 3.5 (AUC = 0.92).Conclusion: These analyses confirm the reliability of MSCopilot and show interesting correlations with the EDSS (similar results obtained with the MSFC). MSCopilot was able to highlight nuances in the different stages of MS the MSFC could not capture.

---

Fichiers liés : S2211034821004314.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/10/2021
• Auteurs : Floriane PailleuxPauline MaesMichel JaquinodJustine BarthelonMarion DarnaudClaire LacosteYves VandenbrouckBenoît GilquinMathilde LouwagieAnne-Marie HesseAlexandra KrautJérôme GarinVincent LeroyJean-Pierre ZarskiChristophe BruleyYohann CoutéDidier SamuelPhilippe IchaiJamila FaivreVirginie Brun
• Organismes : BioSanté BioSanté BioSanté BioSanté Centre Hospitalier Universitaire [CHU Grenoble] Physiopathologie et traitement des maladies du foie Faculté de Médecine Paris-Saclay Physiopathologie et traitement des maladies du foie Faculté de Médecine Paris-Saclay BioSanté BioSanté Clinatec - Centre de recherche biomédicale Edmond J.Safra BioSanté BioSanté BioSanté BioSanté Centre Hospitalier Universitaire [CHU Grenoble] Institute for Advanced Biosciences / Institut pour l'Avancée des Biosciences (Grenoble) Centre Hospitalier Universitaire [CHU Grenoble] Institute for Advanced Biosciences / Institut pour l'Avancée des Biosciences (Grenoble) BioSanté BioSanté Physiopathologie et traitement des maladies du foie Faculté de Médecine Paris-Saclay Physiopathologie et traitement des maladies du foie Faculté de Médecine Paris-Saclay Physiopathologie et traitement des maladies du foie Assistance publique - Hôpitaux de Paris (AP-HP) BioSanté Clinatec - Centre de recherche biomédicale Edmond J.Safra
• Publié dans International Journal of Molecular Sciences le 03/05/2024

---

Résumé : Acute liver injury (ALI) is a severe disorder resulting from excessive hepatocyte cell death, and frequently caused by acetaminophen intoxication. Clinical management of ALI progression is hampered by the dearth of blood biomarkers available. In this study, a bioinformatics workflow was developed to screen omics databases and identify potential biomarkers for hepatocyte cell death. Then, discovery proteomics was harnessed to select from among these candidates those that were specifically detected in the blood of acetaminophen-induced ALI patients. Among these candidates, the isoenzyme alcohol dehydrogenase 1B (ADH1B) was massively leaked into the blood. To evaluate ADH1B, we developed a targeted proteomics assay and quantified ADH1B in serum samples collected at different times from 17 patients admitted for acetaminophen-induced ALI. Serum ADH1B concentrations increased markedly during the acute phase of the disease, and dropped to undetectable levels during recovery. In contrast to alanine aminotransferase activity, the rapid drop in circulating ADH1B concentrations was followed by an improvement in the international normalized ratio (INR) within 10–48 h, and was associated with favorable outcomes. In conclusion, the combination of omics data exploration and proteomics revealed ADH1B as a new blood biomarker candidate that could be useful for the monitoring of acetaminophen-induced ALI.

---

Fichiers liés : ijms-22-11071-v2.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/10/2021
• Auteurs : Stephen AlexanderArthur ChristopoulosAnthony DavenportEamonn KellyAlistair MathieJohn PetersEmma VealeJane ArmstrongElena FaccendaSimon HardingAdam PawsonChristopher SouthanJamie DaviesMaria Pia AbbracchioWayne AlexanderKhaled Al-HosainiMagnus BäckNicholas BarnesRoss BathgateJean‐martin BeaulieuKenneth BernsteinBernhard BettlerNigel J.M. BirdsallVictoria BlahoFrancois BoulayCorinne BousquetHans Bräuner-OsborneGeoffrey BurnstockGirolamo CalóJusto CastañoKevin CattStefania CerutiPaul ChazotNan ChiangBice ChiniJerold ChunAntonia CianciulliOlivier CivelliLucie ClappRéjean CoutureZsolt CsabaClaes DahlgrenGordon DentKhuraijam Dhanachandra SinghSteven DouglasPascal DournaudSatoru EguchiEmanuel EscherEdward FilardoTung FongMarta FumagalliRaul GainetdinovMarc De GasparoCraig GerardMarvin GershengornFernand GobeilTheodore GoodfriendCyril GoudetKaren GregoryAndrew GundlachJörg HamannJulien HansonRichard HaugerDebbie HayAkos HeinemannMorley HollenbergNicholas HollidayMastgugu HoriuchiDaniel HoyerLászló HunyadyAhsan HusainAdriaan IjzermanTadashi InagamiKenneth JacobsonRobert JensenRalf JockersDeepa JonnalagaddaSadashiva KarnikKlemens KaupmannJacqueline KempCharles KennedyYasuyuki KiharaTakio KitazawaPawel KozielewiczHans‐jürgen KreienkampJyrki KukkonenTobias LangenhanKatie LeachDavide LeccaJohn LeeSusan LeemanJérôme LeprinceXaria LiTom Lloyd WilliamsStephen LolaitAmelie LuppRobyn MacraeJanet MaguireJean MazellaCraig McardleShlomo MelmedMartin MichelLaurence MillerVincenzo MitoloBernard MouillacChrista MüllerPhilip MurphyJean‐Louis NahonTony NgoXavier NorelDuuamene NyimanuAnne‐marie O’carrollStefan OffermannsMaria Antonietta PanaroMarc ParmentierRoger PertweeJean-Philippe PinEric ProssnitzMark QuinnRithwik RamachandranManisha RayRainer ReinscheidPhilippe RondardG. Enrico RovatiChiara RuzzaGareth SangerTorsten SchönebergGunnar SchulteStefan SchulzDeborah SegaloffCharles SerhanLeigh StoddartYukihiko SugimotoRoger SummersValerie TanDavid ThalPieter TimmermansKalyan TirupulaGiovanni TulipanoHamiyet UnalThomas UngerCeline ValantPatrick VanderheydenDavid VaudryHubert VaudryJean‐pierre VilardagaChristopher WalkerJi Ming WangDonald WardHans‐jürgen WesterGary WillarsTrent WoodruffChengcan YaoRichard Ye
• Organismes : Différenciation et communication neuronale et neuroendocrine Institut de pharmacologie moléculaire et cellulaire Institut de pharmacologie moléculaire et cellulaire
• Publié dans British Journal of Pharmacology le 29/10/2020

---

Résumé : The Concise Guide to PHARMACOLOGY 2021/22 is the fifth in this series of biennial publications. The Concise Guide provides concise overviews, mostly in tabular format, of the key properties of nearly 1900 human drug targets with an emphasis on selective pharmacology (where available), plus links to the open access knowledgebase source of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties. Although the Concise Guide constitutes over 500 pages, the material presented is substantially reduced compared to information and links presented on the website. It provides a permanent, citable, point-in-time record that will survive database updates. The full contents of this section can be found at http://onlinelibrary.wiley.com/doi/bph.15538. G protein-coupled receptors are one of the six major pharmacological targets into which the Guide is divided, with the others being: ion channels, nuclear hormone receptors, catalytic receptors, enzymes and transporters. These are presented with nomenclature guidance and summary information on the best available pharmacological tools, alongside key references and suggestions for further reading. The landscape format of the Concise Guide is designed to facilitate comparison of related targets from material contemporary to mid-2021, and supersedes data presented in the 2019/20, 2017/18, 2015/16 and 2013/14 Concise Guides and previous Guides to Receptors and Channels. It is produced in close conjunction with the Nomenclature and Standards Committee of the International Union of Basic and Clinical Pharmacology (NC-IUPHAR), therefore, providing official IUPHAR classification and nomenclature for human drug targets, where appropriate.

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/10/2021
• Auteurs : Hugo BellutRaphaël PorcherEmmanuelle VaronPierre AsfarYves Le TulzoBruno MégarbaneArmelle MathonnetAnthony DugardAnne VeinsteinKader OuchenirShidasp SiamiJean ReignierArnaud GalboisJoël CoussonSébastien PréauOlivier BaldesiJean‑philippe RigaudBertrand SouweineBenoit MissetFrederic JacobsFlorent DewavrinJean‑paul MiraJean‑pierre Bedos
• Organismes : Centre Hospitalier de Versailles André Mignot Centre for Research in Epidemiology and Statistics | Centre de Recherche Épidémiologie et Statistiques Centre d'épidémiologie Clinique [Hôtel-Dieu] Université Paris Descartes, Sorbonne Paris Cité Hôpital Européen Georges Pompidou [APHP] CHI Créteil Centre Hospitalier Universitaire d'Angers Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Pontchaillou] Service de Réanimation Médicale et Toxicologique [Hôpital Lariboisière] Hôpital de la source Hôpital Dupuytren [CHU Limoges] Centre hospitalier universitaire de Poitiers = Poitiers University Hospital Hôpital Louis Pasteur [Chartres] Centre Hospitalier Universitaire de Nantes = Nantes University Hospital CHU Saint-Antoine [AP-HP] Hôpital universitaire Robert Debré [Reims] Hôpital Albert Calmette Centre Hospitalier du Pays d'Aix Service de réanimation polyvalente [Centre Hospitalier de Dieppe] CHU Gabriel Montpied [Clermont-Ferrand] Centre hospitalier Saint-Joseph [Paris] AP-HP - Hôpital Antoine Béclère [Clamart] Centre hospitalier [Valenciennes, Nord] Hôpital Cochin [AP-HP] Centre Hospitalier de Versailles André Mignot
• Publié dans Annals of Intensive Care le 23/10/2020

---

Résumé : Background The presence of bacteraemia in pneumococcal pneumonia in critically ill patients does not appear to be a strong independent prognostic factor in the existing literature. However, there may be a specific pattern of factors associated with mortality for ICU patients with bacteraemic pneumococcal community-acquired pneumonia (CAP). We aimed to compare the factors associated with mortality, according to the presence of bacteraemia or not on admission, for patients hospitalised in intensive care for severe pneumococcal CAP. Methods This was a post hoc analysis of data from the prospective, observational, multicentre STREPTOGENE study in immunocompetent Caucasian adults admitted to intensive care in France between 2008 and 2012 for pneumococcal CAP. Patients were divided into two groups based on initial blood culture (positive vs. negative) for Streptococcus pneumoniae . The primary outcome was hospital mortality, which was compared between the two groups using odds ratios according to predefined variables to search for a prognostic interaction present in bacterial patients but not non-bacteraemic patients. Potential differences in the distribution of serotypes between the two groups were assessed. The prognostic consequences of the presence or not of initial bi-antibiotic therapy were assessed, specifically in bacteraemic patients. Results Among 614 included patients, 274 had a blood culture positive for S. pneumoniae at admission and 340 did not. The baseline difference between the groups was more frequent leukopaenia (26% vs. 14%, p = 0.0002) and less frequent pre-hospital antibiotic therapy (10% vs. 16.3%, p = 0.024) for the bacteraemic patients. Hospital mortality was not significantly different between the two groups ( p = 0.11). We did not observe any prognostic factors specific to the bacteraemic patient population, as the statistical comparison of the odds ratios, as an indication of the association between the predefined prognostic parameters and mortality, showed them to be similar for the two groups. Bacteraemic patients more often had invasive serotypes but less often serotypes associated with high case fatality rates ( p = 0.003). The antibiotic regimens were similar for the two groups. There was no difference in mortality for patients in either group given a beta-lactam alone vs. a beta-lactam combined with a macrolide or fluoroquinolone. Conclusion Bacteraemia had no influence on the mortality of immunocompetent Caucasian adults admitted to intensive care for severe pneumococcal CAP, regardless of the profile of the associated prognostic factors.

---

Fichiers liés : HugoBellut_AnnIntensiveCare_2021.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/10/2021
• Auteurs : Sandrine CaputoLisa GolmardMélanie LéoneFrancesca DamiolaMarine Guillaud-BatailleFrançoise RevillionEtienne RouleauNicolas DeriveAdrien BuissonNoémie BassetMathias SchwartzPaul VilquinCeline GarrecMaud PrivatMathilde Gay-BellileCaroline AbadieKhadija AbidallahFabrice AiraudAnne-Sophie AllaryEmmanuelle Barouk-SimonetMuriel BelottiCharlotte BenigniPatrick BenusiglioChristelle BertheminPascaline BerthetOphelie BertrandStéphane BézieauMarie BidartYves-Jean BignonAnne-Marie BirotMaud BlanluetAmelie BloucardJohny BombledValerie BonadonaFrançoise BonnetMarie-Noëlle Bonnet-DupeyronManon BoulaireFlavie BoulouardAhmed BourasViolaine BourdonAfane BrahimiFanny BrayotelBrigitte Bressac de PailleretsNoémie BronnecVirginie BubienBruno BuecherOdile CabaretJennifer CarriereJean ChiesaStephanie Chieze-ValéroCamille CohenOdile Cohen-HaguenauerChrystelle ColasMarie-Agnès Collonge-RameAnne-Laure ConoyFlorence CouletIsabelle CoupierLouise CrivelliVéronica CusinAntoine de PauwCatherine DehainaultHélène DelhomelleCapucine DelnatteSophie DemontetyPhilippe DenizeauPierre DevulderHelene DreyfusCatherine Dubois D’engheinAnaïs DupréAnne DurlachSophie DussartAnne FajacSamira FekairiSandra Fert-FerrerAlice FiévetRobin FouilletEmmanuelle Mouret-FourmeMarion Gauthier-VillarsPaul GestaSophie GiraudLaurence GladieffVeronica GoldbargVincent GoussotVirginie GuibertErell GuillermChristophe GuyAgnès HardouinCéline HeudeClaude HoudayerOlivier IngsterCaroline Jacquot-SawkaNatalie JonesSophie KriegerSofiane LacosteHakima LallaouiHelene LarbreAnthony LaugéGabrielle Le GuyadecMarine Le MentecCaroline LecerfJessica Le GallBérengère LegendreClémentine LegrandAngélina LegrosSophie LejeuneRosette LidereauNorbert LignonJean-Marc LimacherSarab LizardMichel LongyAlain LortholaryPierre MacquereAudrey MailliezSarah MalsaHenri MargotVéronique MariChristine MaugardCindy MeiraJulie MenjardDiane MolièreVirginie MoncoutierJessica Moretta-SerraEtienne MullerZoe NevièreThien-Vu Nguyen Minh TuanTetsuro NoguchiCatherine NoguèsFlorine OcaCornel PopoviciFabienne PrieurSabine RaadJean-Marc ReyAgathe RicouLucie SalleClaire SauleNicolas SevenetFatoumata SimagaHagay SobolVoreak SuybengIsabelle TennevetHenrique TenreiroJulie TinatChristine ToulasIsabelle TurbiezNancy UhrhammerPierre Vande PerreDominique VaurLaurence VenatNicolas ViellardMarie-Charlotte VillyMathilde WarcoinAlice YvardHelene ZattaraOlivier CaronChristine LassetAudrey RemenierasNadia Boutry-KryzaLaurent CastéraDominique Stoppa-Lyonnet
• Organismes : Service de Génétique Oncologique Université Paris Sciences et Lettres Département de Biologie des Tumeurs Unité de génétique et biologie des cancers Hospices Civils de Lyon Centre Léon Bérard [Lyon] CHU Pitié-Salpêtrière [AP-HP] Institut Gustave Roussy Génétique (Biologie pathologie) Institut de biochimie et génétique cellulaires Centre Léon Bérard [Lyon] CHU Pitié-Salpêtrière [AP-HP] Hopital Saint-Louis [AP-HP] Centre Hospitalier Universitaire de Nantes = Nantes University Hospital Centre Jean Perrin [Clermont-Ferrand] Imagerie Moléculaire et Stratégies Théranostiques Imagerie Moléculaire et Stratégies Théranostiques Centre Jean Perrin [Clermont-Ferrand] Imagerie Moléculaire et Stratégies Théranostiques Centre de Références Cancers Rares Institut national du cancer Hôpital Européen Georges Pompidou [APHP] Institut de Cancérologie de l'Ouest [Angers/Nantes] Centre Hospitalier Universitaire de Nantes = Nantes University Hospital Imagerie Moléculaire et Stratégies Théranostiques Centre Jean Perrin [Clermont-Ferrand] Hôpital universitaire Robert Debré [Reims] Imagerie Moléculaire et Stratégies Théranostiques Centre Jean Perrin [Clermont-Ferrand]
• Publié dans American Journal of Human Genetics le 29/10/2020

---

Fichiers liés : S0002929721003396.pdf

---

Source